このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Lyell Immunopharma 過去の業績

過去基準チェック /06

Lyell Immunopharmaの収益は年間平均-4.3%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 26.5%割合で増加しています。

主要情報

-4.3%

収益成長率

99.6%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	26.5%
株主資本利益率	-37.9%
ネット・マージン	-335,794.1%
前回の決算情報	31 Mar 2024

Recent updates

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17

収支内訳

Lyell Immunopharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:LYEL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	0	-228	61	181
31 Dec 23	0	-235	67	183
30 Sep 23	49	-190	80	174
30 Jun 23	48	-209	91	172
31 Mar 23	84	-182	102	168
31 Dec 22	85	-183	117	159
30 Sep 22	39	-258	123	140
30 Jun 22	42	-237	118	130
31 Mar 22	9	-263	107	133
31 Dec 21	11	-250	89	139
30 Sep 21	10	-205	72	154
30 Jun 21	8	-192	59	153
31 Mar 21	9	-230	52	201
31 Dec 20	8	-208	47	182
31 Dec 19	1	-131	39	64

質の高い収益: LYELは現在利益が出ていません。

利益率の向上: LYELは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: LYELは利益が出ておらず、過去 5 年間で損失は年間4.3%の割合で増加しています。

成長の加速: LYELの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: LYELは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: LYELは現在利益が出ていないため、自己資本利益率 ( -37.86% ) はマイナスです。

Lyell Immunopharma 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Full year 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in FY 2022)

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.15 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.28 loss in 1Q 2022)

Full year 2022 earnings released: US$0.74 loss per share (vs US$1.84 loss in FY 2021)

Recent updates

Price target decreased by 44% to US$3.67

Consensus EPS estimates fall by 0.05%

Lyell Immunopharma Reports Dose-Dependent Clinical Activity from Phase 1 Trial of Lyl797, A Ror1-Targeted Car-T Cell Product Candidate Enhanced with Its Proprietary Anti-Exhaustion Technology

Consensus revenue estimates increase by 400%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

Lyell Immunopharma, Inc., Annual General Meeting, Jun 14, 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Full year 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in FY 2022)

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) completed the acquisition of CERo Therapeutics, Inc.

New major risk - Share price stability

Consensus revenue estimates increase by 378%

Price target decreased by 7.1% to US$6.50

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2022)

Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Consensus revenue estimates increase by 25%

Founder & Executive Chairman recently sold US$132k worth of stock

Founder & Executive Chairman notifies of intention to sell stock

Consensus revenue estimates decrease by 96%, EPS upgraded

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.15 loss in 2Q 2022)

Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer

New major risk - Share price stability

Lyell Immunopharma, Inc. Announce Resignation of Rahsaan Thompson as the Chief Legal Officer

Price target decreased by 23% to US$7.25

Consensus revenue estimates decrease by 87%, EPS upgraded

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.28 loss in 1Q 2022)

Price target decreased by 7.8% to US$9.40

Price target decreased by 9.3% to US$9.80

Full year 2022 earnings released: US$0.74 loss per share (vs US$1.84 loss in FY 2021)

Lyell Immunopharma, Inc. Appoints Lynn Seely as President

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 18%

High number of new directors

Price target decreased to US$12.80

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lyell Immunopharma Announces Fda Clearance of Its Ind for Lyl845, A Til Product Candidate Enhanced with Its Novel Epigenetic Reprogramming Technology for Solid Tumors

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Founder & Executive Chairman recently sold US$71k worth of stock

Lyell Immunopharma, Inc. Announces the Appointment of Rahsaan W. Thompson as Chief Legal Officer

Founder & Executive Chairman notifies of intention to sell stock

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Consensus forecasts updated

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$1.47 loss in 2Q 2021)

Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 28%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

High number of new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 37%

Independent Director exercised options to buy US$6.9m worth of stock.

Lyell Immunopharma Announces Executive Changes

Lyell Immunopharma, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for LYL132

High number of new directors

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma, Inc. Announces FDA Clearance of its IND for LYL797

Lyell Immunopharma, Inc. Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

Third quarter 2021 earnings released: US$0.20 loss per share

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Lyell Immunopharma, Inc. has completed an IPO in the amount of $425 million.

収支内訳

過去基準チェック /06